Journal
BRITISH JOURNAL OF OPHTHALMOLOGY
Volume 106, Issue 10, Pages 1332-1337Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/bjophthalmol-2021-319530
Keywords
drugs; glaucoma; pharmacology
Categories
Funding
- NIH [R01EY030851]
- NSF DMS [1853222/2021192]
- Research to Prevent Blindness, New York, USA
Ask authors/readers for more resources
Carbonic anhydrase inhibitors have been used in the treatment of glaucoma for many years, but are no longer the primary treatment method due to common side effects. Topical CAIs are still used in combination therapies and have been shown to have an impact on glaucoma management.
Carbonic anhydrase inhibitors (CAIs) have been used for many decades in the treatment of glaucoma. Systemic CAIs were an early treatment option to lower intraocular pressure by reducing aqueous humour production; however, frequent side effects including polyuria and paresthesia contributed to the eventual development of topical CAIs. As topical drug development evolved over time, prostaglandin analogues and beta-blockers have become the gold standard of glaucoma therapies. Although prescribed less often than other classes of topical glaucoma therapies, topical CAIs continue to be used in combination therapies with beta-blockers and alpha agonists. Topical CAIs have also been demonstrated to alter biomarkers of ocular haemodynamics, which have relevance in glaucoma. The purpose of this review is to review and summarise the current state of topical CAI prescribing trends, known efficacy and suggested mechanisms and potential influence on ocular haemodynamics for the future of glaucoma management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available